Showing 1041-1050 of 7549 results for "".
A Picture is Worth 1,000 Words: Dermatology and eCOA Remote Image Capture Technology
https://practicaldermatology.com/topics/digital-practice/a-picture-is-worth-1000-words-dermatology-and-ecoa-remote-image-capture-technology/26955/A Picture is Worth 1,000 Words: Dermatology and eCOA Remote Image Capture TechnologyEnhancing Dermatopathologic Precision: Submitting Clinical Photographs with Biopsies Should Become Standard of Care in Difficult-to-Diagnose Cases
https://practicaldermatology.com/topics/editorial/enhancing-dermatopathologic-precision-submitting-clinical-photographs-with-biopsies-should-become-standard-of-care-in-difficult-to-diagnose-cases/26969/Enhancing Dermatopathologic Precision: Submitting Clinical Photographs with Biopsies Should Become Standard of Care in Difficult-to-Diagnose CasesAmerican Academy of Dermatology 2024
Meeting Wrap-Uphttps://practicaldermatology.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topicalDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyCamera Ready: How to Work with Media
https://practicaldermatology.com/topics/practice-management/camera-ready-how-to-work-with-media/18661/Hilary Baldwin, MD talks to host Neal Bhatia, MD about working with the media on this edition of Derm Insider. Her number one piece of advice: Make sure you know what you're doing and that you should be doing it, and know when to pass. If you do an interview, be passionate and have two to three keyJournal Club: Pediatric Treatment Adherence
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-pediatric-treatment-adherence/32401/Practical Dermatology Editorial Board members Lawrence Eichenfield, MD, FAAD, Jason Hawkes, MD, MS FAAD, discuss the article "Treatment Adherence in Pediatric Atopic Dermatitis: A Systemic Review," from Pediatric Dermatology as well as their favorite strategies for treatment adherence and the impactAAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JADermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age aCombatting Disparities in Dermatology
https://practicaldermatology.com/topics/general-topics/combatting-disparities-in-dermatology/18338/Research shows disparities in dermatology exisit. Junko Takeshita, MD, PhD, MSCE discusses some examples, such as racial disaparities in which patients recieve biolgics to treat severe psoriasis. She also shares tips on how to determine what implicit biases you may have to race, gender, weight, etc.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.